Clinical Studies

MOCA I Study

First-in-Human study to assess the CoFI device related safety and the feasibility of the diagnostic and the therapeutic sequence as well as the correlation between the dynamic microvascular resistance (dMVR) and microvascular obstruction (MVO) as measured by MRI in patients presenting with acute ST-elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI).
Read more..

Late Breaker:  MOCA I Study presented at EuroPCR 2023

Real-time catheter-based microvascular obstruction detection in STEMI: Results from the MOCA I Study presented by Marco Valgimigli, MD

Future Studies: MOCA II US Pivotal Study

CorFlow is developing a medical device that will be the first to diagnose MVO in real-time during PCI and serve as a treatment platform in the cath lab.

Twitter Linkedin
Who we are
Clinical
News
Our Office
  • +41 41 399 18 00
  • CorFlow Therapeutics AG Neuhofstrasse 3d 6340 Baar, Switzerland
  • contact@corflow.ch

The CoFI-System is not approved in the United States of America.  It is an investigational device limited by federal law to investigational use and is not available for commercial distribution.

VAT:CHE 320.873.257 MWST

© 2023 Corflow. All Rights Reserved.

Cookie Policy | Privacy Policy | Site Map | Impressum